Right to health activists demand release of the full text of EU-India trade deal

The demand by the Working Group on Access to Medicines and Treatment for the full text of the EU-India Free Trade Agreement (FTA) highlights a critical intersection of trade policy, intellectual property rights, and public health. This issue is particularly pertinent for India, a nation often referred to as the 'pharmacy of the world' due to its robust generic pharmaceutical industry and its significant role in supplying affordable medicines globally. **Background Context and What Happened:** Negotiations for a comprehensive EU-India FTA, officially known as the Broad-based Trade and Investment Agreement (BTIA), began in 2007 but were suspended in 2013 due to significant differences on key issues. After a hiatus of nearly nine years, negotiations were formally relaunched in June 2022, signaling a renewed commitment from both sides to deepen economic ties. The EU is one of India's largest trading partners, and a comprehensive FTA is expected to boost trade and investment significantly. However, trade agreements often include provisions on Intellectual Property Rights (IPRs), which can have profound implications for sectors like pharmaceuticals. Right to health activists, represented by the Working Group on Access to Medicines and Treatment, have raised concerns that the ongoing negotiations might include provisions that could negatively impact access to affordable medicines in India. Their primary demand is the release of the full text of the FTA to allow for public scrutiny, especially regarding clauses related to medical treatment and medicine patents. Transparency in trade negotiations is a long-standing demand from civil society, arguing that such agreements, which affect public welfare, should not be negotiated behind closed doors. **Key Stakeholders Involved:** 1. **Working Group on Access to Medicines and Treatment:** This coalition of civil society organizations and activists advocates for policies that ensure widespread access to affordable healthcare and medicines. Their primary concern is that stronger IP provisions in the FTA could lead to higher drug prices, making essential medicines inaccessible to a large segment of the population. 2. **Government of India:** Represented by the Ministry of Commerce and Industry (the lead negotiator) and the Ministry of Health and Family Welfare, the Indian government aims to secure a beneficial trade deal while safeguarding public health interests. Balancing economic gains from increased trade with the imperative of affordable healthcare is a delicate act. 3. **European Union (EU):** The EU, primarily through the European Commission, seeks to protect and enhance its members' pharmaceutical industry interests, which often involve stronger intellectual property protection. They aim to open markets and ensure that innovations are adequately rewarded through patent rights. 4. **Pharmaceutical Industry:** This includes both multinational pharmaceutical companies (largely based in the EU and US) that rely on strong patent protection for their research and development, and the Indian generic pharmaceutical industry, which thrives on producing affordable versions of patented drugs after their patent expiry, or through compulsory licensing. **Why This Matters for India and Historical Context:** India has a unique position as a global leader in generic drug production, supplying affordable medicines to developing countries worldwide. This status is largely built upon its Patents Act, 1970, which initially focused on process patents rather than product patents for pharmaceuticals, thereby encouraging reverse engineering and generic production. While India became compliant with the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement of the WTO in 2005 by introducing product patents, it incorporated crucial public health safeguards. Notably, Section 3(d) of the Patents Act, 1970 (as amended in 2005), prevents 'evergreening' of patents by disallowing patents for minor modifications of existing drugs without enhanced therapeutic efficacy. Furthermore, India has provisions for compulsory licensing under certain conditions, allowing it to override patents in public interest, as affirmed by the Doha Declaration on TRIPS and Public Health (2001). Any provisions in the EU-India FTA that go 'TRIPS-plus' – meaning they impose IP standards beyond those mandated by the TRIPS Agreement – could significantly undermine India's ability to produce and supply affordable generic medicines. This could include demands for data exclusivity, patent term extensions, or stricter enforcement measures, all of which could delay the entry of generics into the market and raise healthcare costs for millions in India and other developing countries reliant on Indian generics. This directly impacts India's public health goals and its constitutional obligation towards its citizens. **Related Constitutional Articles, Acts, or Policies:** * **Article 21 (Right to Life and Personal Liberty):** The Supreme Court has interpreted the 'right to life' to include the right to live with dignity, which encompasses the right to health and medical care. Access to affordable medicines is a crucial component of this fundamental right. * **Article 47 (Directive Principles of State Policy):** This DPSP mandates the State to regard the raising of the level of nutrition and the standard of living of its people and the improvement of public health as among its primary duties. Ensuring access to affordable medicines directly aligns with this directive. * **The Patents Act, 1970 (as amended):** This legislation is the cornerstone of India's IP regime concerning pharmaceuticals. Its public health safeguards are vital for maintaining India's generic drug industry. * **National Health Policy:** India's National Health Policy emphasizes universal access to affordable healthcare, including essential medicines. Trade agreements must align with these domestic policy objectives. **Future Implications:** The outcome of the EU-India FTA negotiations, particularly regarding IP provisions, will have far-reaching implications. It will determine the future landscape of India's pharmaceutical industry, its ability to ensure affordable healthcare for its vast population, and its role as a global supplier of essential medicines. A balanced agreement that respects India's public health safeguards while fostering trade could be a win-win. However, if the FTA includes stringent TRIPS-plus provisions, it could lead to increased drug prices, greater health inequalities, and a potential erosion of India's 'pharmacy of the world' status. The demand for transparency is a step towards ensuring that public interest is not compromised in the pursuit of economic gains, reflecting broader themes of good governance and international relations where national sovereignty over public health policies is asserted.